Developer docs
API playgroundTry for free, no card

Search company profiles

Brainsway

Full company profile

uuid0000xcz

Namestring
Brainsway
Legal namestring
BrainsWay Ltd.
Websiteurl
brainsway.com
Company typeenum
Public
Founded yearint
2003
Descriptiontext

BrainsWay Ltd. is a publicly traded Israeli medical technology company (NASDAQ: BWAY; TASE) founded in 2003 that develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) systems for treating psychiatric and neurological disorders. The company's core technology is a proprietary H-coil platform fitted into a cushioned helmet that generates electromagnetic fields reaching deeper and broader brain regions than first-generation (figure-8 coil) TMS devices; coil variants include the H1 for MDD, H4 for smoking addiction, and H7 for OCD. BrainsWay holds FDA clearances for MDD (including anxious, late-life, and adolescent subtypes), OCD, and smoking cessation, plus CE marks for conditions including PTSD, autism, Alzheimer's, Parkinson's, and chronic pain.

The company generates revenue by selling and leasing Deep TMS systems to mental health clinics, hospitals, and outpatient psychiatric practices, with an installed base of approximately 1,820 systems across 800+ provider locations in 35+ countries. The leasing model produces high-margin recurring revenue, and BrainsWay supplements direct sales with strategic minority investments in provider chains (Hopemark Health, BrainStim Health, Axis Integrated Mental Health, Heading Health, Stella MSO) to drive adoption and expand access. Insurance coverage has expanded rapidly, with eight major payers and the US VA covering the SWIFT accelerated protocol (over 57 million covered lives), and adolescent MDD coverage reaching approximately 180 million lives following Optum Behavioral Health expansion.

Short descriptiontext

BrainsWay is an Israeli medical technology company that develops and commercializes proprietary Deep TMS (Transcranial Magnetic Stimulation) systems using patented H-coil technology for treating psychiatric disorders including depression, OCD, and smoking addiction, selling and leasing to healthcare providers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcranial magnetic stimulation, deep TMS systems, neurostimulation medical devices, brain stimulation therapy, mental health treatment devices
Industry2 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Neuromodulation Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Deep TMS System Sales and Leasing
TypeHardware Sales
Description

BrainsWay generates revenue from the sale and leasing of its Deep TMS systems to mental health clinics, hospitals, and outpatient practices. An expanded leasing model drives high-margin recurring revenue. Record 117 systems shipped in Q1 2026 and approximately 1,820 total systems installed.

seekingalpha.com
2Recurring Revenue (Leasing Model)
TypeSubscription Recurring
Description

With approximately 1,820 systems installed, the leasing model generates recurring revenue from existing installed base. The shift to leasing expanded margins and drove 27% revenue growth in 2025 with 161% increase in net income to $7.6 million.

seekingalpha.com
3Strategic Minority Investments in Mental Health Providers
TypeManaged Services
Description

BrainsWay makes minority stake investments in mental health provider chains (Hopemark Health, Axis Integrated Mental Health, BrainStim Health, Heading Health, Stella MSO) as part of a strategy to expand access and awareness of its Deep TMS technology. These are equity investments that may generate returns through provider network growth and utilization.

bhbusiness.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details2 tiers
1Deep TMS system sale or lease to healthcare providers
ModelSubscriptionBilling cadenceAnnual
Notes

BrainsWay offers both system sales and leasing options. The leasing model generates recurring revenue. Specific pricing terms are negotiated individually with providers and not publicly disclosed.

brainsway.com
2Treatment procedure revenue for providers (per session or bundled)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Providers bill insurance per TMS session. Coverage varies by payer: Medicare and majority of private insurers cover Deep TMS for MDD; coverage expanding for OCD and adolescent use. SWIFT accelerated protocol covered by major payers including BCBS South Carolina, representing 2 million members.

globenewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Deep TMS
Description

Deep Transcranial Magnetic Stimulation technology platform for treating mental health disorders including depression, OCD, and smoking addiction

brainsway.com
+2 more records
Core offering1 text field

BrainsWay designs, manufactures, and sells/leases Deep Transcranial Magnetic Stimulation (Deep TMS) medical devices built around its proprietary H-coil technology. Healthcare providers such as mental health clinics, outpatient psychiatric practices, and hospitals purchase or lease these systems to deliver noninvasive brain stimulation treatments for FDA-cleared indications including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction, as well as CE-marked indications such as PTSD and autism.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BrainsWay is a global medical technology company offering the Deep TMS (Deep Transcranial Magnetic Stimulation) platform as its core product, featuring proprietary patented H-coil technology. The platform has achieved multiple FDA clearances for treating Major Depressive Disorder (including anxious and late-life depression), Obsessive Compulsive Disorder, and Smoking Addiction. The portfolio includes standard Deep TMS protocols with 20-minute sessions and the SWIFT Accelerated Deep TMS protocol reducing treatment to 6 days. Additional products include Deep TMS 360 (next-generation multichannel system in clinical trials for Alcohol Use Disorder), and CE-marked treatments for PTSD and Autism. The company operates a provider network with over 800 clinics worldwide offering these treatments.

Product and service10 records
1Deep TMS Platform
CategoryNeurostimulation Medical Devices
Description

Core Deep Transcranial Magnetic Stimulation device using patented H-coil technology housed in a cushioned helmet to generate electromagnetic fields that reach deeper and broader brain regions than first-generation figure-8 TMS coils, sold or leased to mental health clinics, hospitals, and outpatient psychiatric practices.

2Deep TMS for Major Depressive Disorder (MDD)
CategoryNeurostimulation Medical Devices
Description

FDA-cleared Deep TMS treatment for adult patients with MDD who failed to achieve improvement from previous antidepressant medication, delivered via standard 20-minute sessions over 4 weeks using the H1 coil targeting the dorsolateral prefrontal cortex.

3Deep TMS for Obsessive-Compulsive Disorder (OCD)
CategoryNeurostimulation Medical Devices
Description

First FDA-cleared noninvasive medical device for OCD, using the H7 coil to target the anterior cingulate cortex and medial prefrontal cortex with a six-week protocol of 18-minute sessions; 38.1% full response rate vs 11.1% sham in pivotal trial.

4Deep TMS for Smoking Addiction
CategoryNeurostimulation Medical Devices
Description

FDA-cleared Deep TMS aid for short-term smoking cessation in adults using the H4 coil targeting the bilateral insula and prefrontal cortex, delivered as 18 sessions over 6 weeks including brief provocation and counseling; 28.0% continuous quit rate vs 11.7% sham in pivotal trial of 262 patients.

5Deep TMS for Anxious Depression
CategoryNeurostimulation Medical Devices
Description

First TMS system FDA-cleared to safely and effectively reduce comorbid anxiety symptoms in adult MDD patients using the H1 coil, with standard Deep TMS protocol.

6Deep TMS for Late-Life Depression
CategoryNeurostimulation Medical Devices
Description

FDA-cleared Deep TMS treatment for depression among patients ages 68-86, leveraging the H-coil design to address age-related increases in scalp-cortical distance.

7SWIFT Accelerated Deep TMS Protocol
CategoryNeurostimulation Medical Devices
Description

Accelerated Deep TMS protocol that compresses the standard 20-visit, 4-week acute treatment phase into 6 half-day sessions over 6 days while maintaining comparable efficacy; sessions shortened to 10 minutes from 20 minutes and coverage extended across eight major payers plus the US VA, representing over 57 million covered lives.

8Deep TMS for Adolescent Depression (ages 15-21)
CategoryNeurostimulation Medical Devices
Description

FDA-cleared Deep TMS adjunct therapy for adolescents aged 15 to 21 with major depressive disorder, extending coverage to an estimated 5 million adolescents in the US across approximately 180 million covered lives following Optum Behavioral Health policy update.

9Deep TMS 360
CategoryNeurostimulation Medical Devices
Description

Next-generation multichannel Deep TMS platform enabling more targeted and broader stimulation across multiple brain networks simultaneously, used in the first multicenter clinical trial for Alcohol Use Disorder and supported by an approximately $2.5 million NIH grant to Stanford and the Palo Alto Veterans Institute for Research.

10Deep TMS for PTSD
CategoryNeurostimulation Medical Devices
Description

CE-marked and ANVISA-approved Deep TMS treatment for Post-Traumatic Stress Disorder using magnetic stimulation of brain structures related to PTSD, currently not commercially available in the US and under continued clinical investigation (not FDA-cleared).

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
1Hopemark Health
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-18
Description

$1.5 million strategic minority-stake investment in Hopemark Health, a Chicago-area mental health provider with multiple clinic locations (Orland Park, Hoffman Estates, Naperville, Oak Brook), with potential for additional $1.5 million through milestone-based financing. Hopemark Health, founded by Dr. Abid Nazeer in 2016, provides integrated outpatient psychiatric care including ketamine-based therapies and TMS treatments. This represents BrainsWay's strategy to expand access and awareness of Deep TMS across North America.

pulse2.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

$6 million milestone-based convertible loan investment in Neurolief triggered by FDA Premarket Approval of Neurolief's ProlivRx at-home brain neuromodulation system for major depressive disorder (December 2025). This second tranche brings BrainsWay's total investment in Neurolief to $11 million, with potential third tranche of up to $5 million upon revenue-based milestone. BrainsWay also holds a call option to acquire all outstanding equity in Neurolief during defined exercise windows. ProlivRx is the first FDA-approved at-home prescription neuromodulation therapy for MDD, included in Veterans Affairs Federal Supply Schedule.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

$1 million milestone-based investment in Axis Management Company, Inc. (Axis Integrated Mental Health) following achievement of a predefined revenue milestone. BrainsWay holds a minority stake through a preferred security. Axis operates mental health clinics in Colorado and has successfully deployed capital and grown under the partnership, integrating advanced neurostimulation treatments with comprehensive psychiatric and therapeutic services.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

$1.0 million initial minority-stake investment in BrainStim Health Inc., a British Columbia-based mental health provider with clinics across Canada, with potential for additional $1.5 million through milestone-based investments. BrainStim specializes in treating veterans and first responders with conditions including severe trauma, stress, anxiety, and depression. This is BrainsWay's fifth minority-stake investment into growth-oriented clinical service platforms, taking the form of a preferred, annually compounding security with redemption mechanism.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-27
Description

Minority stake investment in Heading Health, a mental health provider with locations in Texas (Austin), involving an initial $1.5 million with potential up to $2.5 million, aimed at expanding access to neurostimulation treatments for mental health conditions. Part of BrainsWay's broader strategy of minority investments in mental health provider platforms.

6Stella MSO, LLC
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-04
Description

$5 million minority-stake investment in Stella MSO, LLC, a management services organization supporting mental health clinics in the U.S. and Israel. The investment grants BrainsWay a minority stake through a preferred security to facilitate growth and positive patient outcomes, as part of strategic efforts to expand access to neurostimulation treatments.

globenewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Addresses the same treatment-resistant MDD population via an alternative interventional psychiatry modality.

TypeEmerging player
Description

Commercializes non-invasive vagus nerve stimulation (nVNS) devices for migraine, cluster headache, and indications including depression. Competes in the broader non-invasive neuromodulation category addressing treatment-resistant mental health and headache conditions.

TypeOthers
Description

Commercial-stage CNS pharmaceutical company with FDA-approved therapies for major depressive disorder (Auvelity) and migraine. Adjacent competitor for the same MDD patient pool where Deep TMS is used, particularly treatment-resistant depression.

TypeBroad incumbent
Description

Global medical device company with an implantable vagus nerve stimulation (VNS) system approved for treatment-resistant depression. Competes in the neuromodulation-for-depression category but with an invasive surgical approach versus BrainsWay's non-invasive TMS.

TypeDirect peer
Description

Finland-headquartered company offering navigated TMS systems for depression and pre-surgical brain mapping. Comparable in providing TMS-based therapy devices targeting psychiatric indications and overlapping clinical customer base.

TypeRegional player
Description

Developer of Evoke, a closed-loop spinal cord stimulation system for chronic pain. Operates in the broader implanted neuromodulation space that parallels BrainsWay's neurostimulation franchise, though targeting different indications and geographies.

TypeDirect peer
Description

U.S. medical device company commercializing NeuroStar, the leading figure-8 coil TMS system for MDD and OCD. Direct competitor selling TMS hardware to the same psychiatrist and clinic customers that BrainsWay targets, with overlapping FDA-cleared indications.

8Magstim
TypeDirect peer
Description

UK-based manufacturer of TMS stimulators and coils used in research and clinical psychiatry globally. Competes head-to-head with BrainsWay's Deep TMS by offering alternative TMS platforms to clinics and academic centers.

TypeOthers
Description

U.S. and Canadian operator of a large TMS clinic network and a major customer/competitor dynamic for BrainsWay and Neuronetics. Comparable as a high-volume provider of TMS services and a key channel for Deep TMS system sales.

TypeEmerging player
Description

Developer of ProlivRx, the first FDA-approved at-home prescription neuromodulation therapy for MDD. Comparable as a non-invasive neurostimulation competitor; BrainsWay is also a strategic investor via an $11M convertible loan with an acquisition call option.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brainsway

Neuromodulation Medical Devicesbrainsway.com

BrainsWay is an Israeli medical technology company that develops and commercializes proprietary Deep TMS (Transcranial Magnetic Stimulation) systems using patented H-coil technology for treating psychiatric disorders including depression, OCD, and smoking addiction, selling and leasing to healthcare providers globally.

What Brainsway does

BrainsWay Ltd. is a publicly traded Israeli medical technology company (NASDAQ: BWAY; TASE) founded in 2003 that develops and commercializes Deep Transcranial Magnetic Stimulation (Deep TMS) systems for treating psychiatric and neurological disorders. The company's core technology is a proprietary H-coil platform fitted into a cushioned helmet that generates electromagnetic fields reaching deeper and broader brain regions than first-generation (figure-8 coil) TMS devices; coil variants include the H1 for MDD, H4 for smoking addiction, and H7 for OCD. BrainsWay holds FDA clearances for MDD (including anxious, late-life, and adolescent subtypes), OCD, and smoking cessation, plus CE marks for conditions including PTSD, autism, Alzheimer's, Parkinson's, and chronic pain.

The company generates revenue by selling and leasing Deep TMS systems to mental health clinics, hospitals, and outpatient psychiatric practices, with an installed base of approximately 1,820 systems across 800+ provider locations in 35+ countries. The leasing model produces high-margin recurring revenue, and BrainsWay supplements direct sales with strategic minority investments in provider chains (Hopemark Health, BrainStim Health, Axis Integrated Mental Health, Heading Health, Stella MSO) to drive adoption and expand access. Insurance coverage has expanded rapidly, with eight major payers and the US VA covering the SWIFT accelerated protocol (over 57 million covered lives), and adolescent MDD coverage reaching approximately 180 million lives following Optum Behavioral Health expansion.

Brainsway firmographics

Firmographics
Name
Brainsway
Legal name
BrainsWay Ltd.
Website
https://brainsway.com
Company type
Public
Founded year
2003
Operating status
Operating
Headcount range
101–250 employees
Short description
BrainsWay is an Israeli medical technology company that develops and commercializes proprietary Deep TMS (Transcranial Magnetic Stimulation) systems using patented H-coil technology for treating psychiatric disorders including depression, OCD, and smoking addiction, selling and leasing to healthcare providers globally.
Ownership category
akta.pro rank

Brainsway industry classification

Industry
Product category
Neuromodulation Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYCRACAQAL
Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)

Keywords

  • Transcranial magnetic stimulation
  • Deep TMS systems
  • Neurostimulation medical devices
  • Brain stimulation therapy
  • Mental health treatment devices

Where Brainsway is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Brainsway business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Deep TMS System Sales and Leasing: BrainsWay generates revenue from the sale and leasing of its Deep TMS systems to mental health clinics, hospitals, and outpatient practices. An expanded leasing model drives high-margin recurring revenue. Record 117 systems shipped in Q1 2026 and approximately 1,820 total systems installed.
  2. Recurring Revenue (Leasing Model): With approximately 1,820 systems installed, the leasing model generates recurring revenue from existing installed base. The shift to leasing expanded margins and drove 27% revenue growth in 2025 with 161% increase in net income to $7.6 million.
  3. Strategic Minority Investments in Mental Health Providers: BrainsWay makes minority stake investments in mental health provider chains (Hopemark Health, Axis Integrated Mental Health, BrainStim Health, Heading Health, Stella MSO) as part of a strategy to expand access and awareness of its Deep TMS technology. These are equity investments that may generate returns through provider network growth and utilization.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualDeep TMS system sale or lease to healthcare providers
Unit PricingPay-as-you-goTreatment procedure revenue for providers (per session or bundled)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Brainsway product offering

Product offering

Core offering

BrainsWay designs, manufactures, and sells/leases Deep Transcranial Magnetic Stimulation (Deep TMS) medical devices built around its proprietary H-coil technology. Healthcare providers such as mental health clinics, outpatient psychiatric practices, and hospitals purchase or lease these systems to deliver noninvasive brain stimulation treatments for FDA-cleared indications including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction, as well as CE-marked indications such as PTSD and autism.

Product overview

BrainsWay is a global medical technology company offering the Deep TMS (Deep Transcranial Magnetic Stimulation) platform as its core product, featuring proprietary patented H-coil technology. The platform has achieved multiple FDA clearances for treating Major Depressive Disorder (including anxious and late-life depression), Obsessive Compulsive Disorder, and Smoking Addiction. The portfolio includes standard Deep TMS protocols with 20-minute sessions and the SWIFT Accelerated Deep TMS protocol reducing treatment to 6 days. Additional products include Deep TMS 360 (next-generation multichannel system in clinical trials for Alcohol Use Disorder), and CE-marked treatments for PTSD and Autism. The company operates a provider network with over 800 clinics worldwide offering these treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • Deep TMS: Deep Transcranial Magnetic Stimulation technology platform for treating mental health disorders including depression, OCD, and smoking addiction
  • SWIFT
  • Deep TMS 360

Products and services

  • Deep TMS Platform Core Deep Transcranial Magnetic Stimulation device using patented H-coil technology housed in a cushioned helmet to generate electromagnetic fields that reach deeper and broader brain regions than first-generation figure-8 TMS coils, sold or leased to mental health clinics, hospitals, and outpatient psychiatric practices.
  • Deep TMS for Major Depressive Disorder (MDD) FDA-cleared Deep TMS treatment for adult patients with MDD who failed to achieve improvement from previous antidepressant medication, delivered via standard 20-minute sessions over 4 weeks using the H1 coil targeting the dorsolateral prefrontal cortex.
  • Deep TMS for Obsessive-Compulsive Disorder (OCD) First FDA-cleared noninvasive medical device for OCD, using the H7 coil to target the anterior cingulate cortex and medial prefrontal cortex with a six-week protocol of 18-minute sessions; 38.1% full response rate vs 11.1% sham in pivotal trial.
  • Deep TMS for Smoking Addiction FDA-cleared Deep TMS aid for short-term smoking cessation in adults using the H4 coil targeting the bilateral insula and prefrontal cortex, delivered as 18 sessions over 6 weeks including brief provocation and counseling; 28.0% continuous quit rate vs 11.7% sham in pivotal trial of 262 patients.
  • Deep TMS for Anxious Depression First TMS system FDA-cleared to safely and effectively reduce comorbid anxiety symptoms in adult MDD patients using the H1 coil, with standard Deep TMS protocol.
  • Deep TMS for Late-Life Depression FDA-cleared Deep TMS treatment for depression among patients ages 68-86, leveraging the H-coil design to address age-related increases in scalp-cortical distance.
  • SWIFT Accelerated Deep TMS Protocol Accelerated Deep TMS protocol that compresses the standard 20-visit, 4-week acute treatment phase into 6 half-day sessions over 6 days while maintaining comparable efficacy; sessions shortened to 10 minutes from 20 minutes and coverage extended across eight major payers plus the US VA, representing over 57 million covered lives.
  • Deep TMS for Adolescent Depression (ages 15-21) FDA-cleared Deep TMS adjunct therapy for adolescents aged 15 to 21 with major depressive disorder, extending coverage to an estimated 5 million adolescents in the US across approximately 180 million covered lives following Optum Behavioral Health policy update.
  • Deep TMS 360 Next-generation multichannel Deep TMS platform enabling more targeted and broader stimulation across multiple brain networks simultaneously, used in the first multicenter clinical trial for Alcohol Use Disorder and supported by an approximately $2.5 million NIH grant to Stanford and the Palo Alto Veterans Institute for Research.
  • Deep TMS for PTSD CE-marked and ANVISA-approved Deep TMS treatment for Post-Traumatic Stress Disorder using magnetic stimulation of brain structures related to PTSD, currently not commercially available in the US and under continued clinical investigation (not FDA-cleared).

Companies that use Brainsway

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles2 records

Brainsway technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Brainsway partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core.

  • Hopemark HealthcoreStrategic or Co-development Partner · 18 May 2026$1.5 million strategic minority-stake investment in Hopemark Health, a Chicago-area mental health provider with multiple clinic locations (Orland Park, Hoffman Estates, Naperville, Oak Brook), with potential for additional $1.5 million through milestone-based financing. Hopemark Health, founded by Dr. Abid Nazeer in 2016, provides integrated outpatient psychiatric care including ketamine-based therapies and TMS treatments. This represents BrainsWay's strategy to expand access and awareness of Deep TMS across North America.
  • Neurolief Ltd.coreStrategic or Co-development Partner · 26 March 2026$6 million milestone-based convertible loan investment in Neurolief triggered by FDA Premarket Approval of Neurolief's ProlivRx at-home brain neuromodulation system for major depressive disorder (December 2025). This second tranche brings BrainsWay's total investment in Neurolief to $11 million, with potential third tranche of up to $5 million upon revenue-based milestone. BrainsWay also holds a call option to acquire all outstanding equity in Neurolief during defined exercise windows. ProlivRx is the first FDA-approved at-home prescription neuromodulation therapy for MDD, included in Veterans Affairs Federal Supply Schedule.
  • Axis Integrated Mental HealthcoreStrategic or Co-development Partner · 19 March 2026$1 million milestone-based investment in Axis Management Company, Inc. (Axis Integrated Mental Health) following achievement of a predefined revenue milestone. BrainsWay holds a minority stake through a preferred security. Axis operates mental health clinics in Colorado and has successfully deployed capital and grown under the partnership, integrating advanced neurostimulation treatments with comprehensive psychiatric and therapeutic services.
  • BrainStim Health Inc.coreStrategic or Co-development Partner · 19 February 2026$1.0 million initial minority-stake investment in BrainStim Health Inc., a British Columbia-based mental health provider with clinics across Canada, with potential for additional $1.5 million through milestone-based investments. BrainStim specializes in treating veterans and first responders with conditions including severe trauma, stress, anxiety, and depression. This is BrainsWay's fifth minority-stake investment into growth-oriented clinical service platforms, taking the form of a preferred, annually compounding security with redemption mechanism.
  • Heading HealthcoreStrategic or Co-development Partner · 27 October 2025Minority stake investment in Heading Health, a mental health provider with locations in Texas (Austin), involving an initial $1.5 million with potential up to $2.5 million, aimed at expanding access to neurostimulation treatments for mental health conditions. Part of BrainsWay's broader strategy of minority investments in mental health provider platforms.
  • Stella MSO, LLCcoreStrategic or Co-development Partner · 4 June 2025$5 million minority-stake investment in Stella MSO, LLC, a management services organization supporting mental health clinics in the U.S. and Israel. The investment grants BrainsWay a minority stake through a preferred security to facilitate growth and positive patient outcomes, as part of strategic efforts to expand access to neurostimulation treatments.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Brainsway competitors and assessment

Company assessment

Emerging players

  • Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression. Addresses the same treatment-resistant MDD population via an alternative interventional psychiatry modality.
  • Electrocore: Commercializes non-invasive vagus nerve stimulation (nVNS) devices for migraine, cluster headache, and indications including depression. Competes in the broader non-invasive neuromodulation category addressing treatment-resistant mental health and headache conditions.
  • Neurolief: Developer of ProlivRx, the first FDA-approved at-home prescription neuromodulation therapy for MDD. Comparable as a non-invasive neurostimulation competitor; BrainsWay is also a strategic investor via an $11M convertible loan with an acquisition call option.

Others

  • Axsome Therapeutics: Commercial-stage CNS pharmaceutical company with FDA-approved therapies for major depressive disorder (Auvelity) and migraine. Adjacent competitor for the same MDD patient pool where Deep TMS is used, particularly treatment-resistant depression.
  • Greenbrook TMS: U.S. and Canadian operator of a large TMS clinic network and a major customer/competitor dynamic for BrainsWay and Neuronetics. Comparable as a high-volume provider of TMS services and a key channel for Deep TMS system sales.

Broad incumbents

  • LivaNova: Global medical device company with an implantable vagus nerve stimulation (VNS) system approved for treatment-resistant depression. Competes in the neuromodulation-for-depression category but with an invasive surgical approach versus BrainsWay's non-invasive TMS.

Direct peers

  • Nexstim: Finland-headquartered company offering navigated TMS systems for depression and pre-surgical brain mapping. Comparable in providing TMS-based therapy devices targeting psychiatric indications and overlapping clinical customer base.
  • Neuronetics: U.S. medical device company commercializing NeuroStar, the leading figure-8 coil TMS system for MDD and OCD. Direct competitor selling TMS hardware to the same psychiatrist and clinic customers that BrainsWay targets, with overlapping FDA-cleared indications.
  • Magstim: UK-based manufacturer of TMS stimulators and coils used in research and clinical psychiatry globally. Competes head-to-head with BrainsWay's Deep TMS by offering alternative TMS platforms to clinics and academic centers.

Regional players

  • Saluda Medical: Developer of Evoke, a closed-loop spinal cord stimulation system for chronic pain. Operates in the broader implanted neuromodulation space that parallels BrainsWay's neurostimulation franchise, though targeting different indications and geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Brainsway social profiles

Digital presence

Brainsway compliance and trust

Trust signal

Compliance3 records

Brainsway financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brainsway leadership team

Management profile

Number of profiles

Profiles13 records

Brainsway subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Brainsway funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brainsway M&A and investment

M&A and investment

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brainsway

What does Brainsway do?

BrainsWay designs, manufactures, and sells/leases Deep Transcranial Magnetic Stimulation (Deep TMS) medical devices built around its proprietary H-coil technology. Healthcare providers such as mental health clinics, outpatient psychiatric practices, and hospitals purchase or lease these systems to deliver noninvasive brain stimulation treatments for FDA-cleared indications including major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and smoking addiction, as well as CE-marked indications such as PTSD and autism.

Is Brainsway a public or private company?

Brainsway is a public company. It is classified as public and is currently operating.

When was Brainsway founded?

Brainsway was founded in 2003. It employs 101 to 250 people.

Where is Brainsway based?

Brainsway is headquartered in Burlington, United States, in the North America region.

How does Brainsway make money?

Three revenue lines are on record. Deep TMS System Sales and Leasing is the primary driver. The others are recurring Revenue (Leasing Model) and strategic Minority Investments in Mental Health Providers.

Who are Brainsway's main competitors?

Emerging players on record are Compass Pathways, Electrocore and Neurolief. Others are Axsome Therapeutics and Greenbrook TMS. LivaNova is listed as a broad incumbent. Direct peers are Nexstim, Neuronetics and Magstim. Saluda Medical is listed as a regional player.

Does Brainsway have an API?

No public API is recorded for Brainsway.

What industry is Brainsway in?

Brainsway's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsBrainsway (NASDAQ:BWAY) Stock Rating Lowered by Wall Street ZenWall Street Zen downgraded Brainsway from a buy to a hold rating. The company reported Q2 EPS of $0.14, beating estimates of $0.10, with revenue of $17.11 million. Analysts have a consensus Moderate Buy rating and an average target price of $18.20.American Banking and Market NewsAnalyzing Becton, Dickinson and Company (NYSE:BDX) and Brainsway (NASDAQ:BWAY)Brainsway and Becton, Dickinson and Company are compared on dividends, valuation, analyst ratings, risk, institutional ownership, earnings, and profitability. Brainsway beats on 8 of 15 factors, with a consensus price target of $18.20 implying 77.56% upside, while BD's target is $197.47 implying 8.46% downside.YahooBrainsWay: 3 Key Takeaways for Long-Term InvestorsBrainsWay reported Q3 2026 revenue of $18.1 million, up 34% year over year, with 130 Deep TMS systems shipped. Gross profit rose 39% to $14.1 million, and gross margin reached 78%. The company expects full-year results toward the upper end of guidance and sees 2027 as a growth phase.The Motley FoolBrainsWay: 3 Key Takeaways for Long-Term InvestorsBrainsWay reported Q3 2026 revenue of $18.1 million, up 34% year over year, with 130 Deep TMS systems shipped. Gross profit rose 39% to $14.1 million, and gross margin reached 78%. The company expects full-year results toward the upper end of guidance and sees 2027 as a growth phase.YahooBrainsWay Ltd (BRSYF) (Q3 2026) Earnings Call Highlights: Revenue Jumps 34% as Margins Expand ...BrainsWay reported Q3 2026 revenue of $18.1 million, up 34% year-over-year, with deep TMS system shipments rising 44% to 130 units. Gross margin improved to 78% and operating income more than doubled to $2.6 million. The company did not provide formal 2027 guidance, citing uncertainty.The Motley FoolBrainsWay (BWAY) Q3 2026 Earnings Call TranscriptBrainsWay reported Q3 2026 revenue of $18.1 million, up 34% year-over-year, driven by 130 system shipments and recurring revenue. Gross margin improved to 78% and operating income rose 107% to $2.6 million. Management updated full-year 2026 guidance to the upper end of its range.The Motley FoolBrainsWay (BWAY) Q3 2026 Earnings Call TranscriptBrainsWay reported Q3 2026 revenue of $18.1 million, up 34% year-over-year, driven by 130 Deep TMS system shipments. Gross margin improved to 78% and operating income rose 107% to $2.6 million. Management updated full-year 2026 guidance to the upper end of its range.MarketBeatWhat Brainsway (BWAY) Said on Its Q3 Earnings CallBrainsway reported Q3 2026 revenue of $18.1 million, up 34% year over year, and operating income of $2.6 million, more than double the prior year. The company shipped 130 Deep TMS systems, up 44%, and expects full-year results at the upper end of its guidance. It also expanded reimbursement coverage for its SWIFT protocol to over 70 million U.S. lives.American Banking and Market NewsComparing Pulmonx (NASDAQ:LUNG) & Brainsway (NASDAQ:BWAY)A comparison of Brainsway and Pulmonx evaluates profitability, valuation, and analyst ratings. Pulmonx shows higher revenue ($90.5M vs $52.2M) but negative earnings, while Brainsway has positive earnings. Analysts favor Pulmonx with a 199.48% upside versus Brainsway's 63.23%.Investing.comH.C. Wainwright reiterates Brainsway stock rating on strategic collaborationH.C. Wainwright reiterated a Buy rating and $19.00 price target on Brainsway after the company announced a strategic collaboration with Mindful Health Solutions. The target implies a 71% upside from the current $11.09 price, and the partnership aims to expand access to noninvasive mental health treatments.